ArticleSkeletal muscle2011
δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.
Article in Skeletal muscle, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- The two faces of mitochondrial CaJournal of physiology and biochemistry · 2026Review
- Development of an anti-CDH15/M-cadherin monoclonal antibody CaBiochemistry and biophysics reports · 2025Article
- Modeling Sarcoglycanopathy inInternational journal of molecular sciences · 2023Article
- Limb-Girdle Muscular Dystrophies Classification and Therapies.Journal of clinical medicine · 2023Review
- Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction.Biomolecules · 2022Review
- Review
- The linkage between inflammation and fibrosis in muscular dystrophies: The axis autotaxin-lysophosphatidic acid as a new therapeutic target?Journal of cell communication and signaling · 2021Review
- Muscular dystrophy: Experimental animal models and therapeutic approaches (Review).Experimental and therapeutic medicine · 2021Review
- Periostin Is Required for the Maintenance of Muscle Fibers during Muscle Regeneration.International journal of molecular sciences · 2021Article
- Pigs with δ-sarcoglycan deficiency exhibit traits of genetic cardiomyopathy.Laboratory investigation; a journal of technical methods and pathology · 2020Article
- Lack of Delta-Sarcoglycan (International journal of molecular sciences · 2019Article
- Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F.PloS one · 2019Article
- Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F.PloS one · 2017Article
- Mutation in δ-Sg Gene in Familial Dilated Cardiomyopathy.Advanced biomedical research · 2017Article
- Dietary Flaxseed Mitigates Impaired Skeletal Muscle Regeneration: in Vivo, in Vitro and in Silico Studies.International journal of medical sciences · 2016Article
- Myocardial Contractile Dysfunction Is Present without Histopathology in a Mouse Model of Limb-Girdle Muscular Dystrophy-2F and Is Prevented after Claudin-5 Virotherapy.Frontiers in physiology · 2016Article
- SIRT1: A Novel Target for the Treatment of Muscular Dystrophies.Oxidative medicine and cellular longevity · 2016Review
- (-)-Epicatechin improves mitochondrial-related protein levels and ameliorates oxidative stress in dystrophic δ-sarcoglycan null mouse striated muscle.The FEBS journal · 2014Article
- SERCA2a gene therapy can improve symptomatic heart failure in δ-sarcoglycan-deficient animals.Human gene therapy · 2014Article
- Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy.Human gene therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Mutations in the δ-sarcoglycan gene cause limb-girdle muscular dystrophy 2F (LGMD2F), an autosomal recessive disease that causes progressive weakness and wasting of the proximal limb muscles and often has cardiac involvement. Here we review the clinical implications of LGMD2F and discuss the current understanding of the putative mechanisms underlying its pathogenesis. Preclinical research has benefited enormously from various animal models of δ-sarcoglycan deficiency, which have helped researchers to explore therapeutic approaches for both muscular dystrophy and cardiomyopathy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.